Report suggests 'breakthrough' Alzheimer's drugs unlikely to benefit patients

A major review has provoked a backlash after concluding the medicines provide too little benefit to be noticed.

Analysis of Alzheimer’s Drugs Stirs Debate About Their Effectiveness

The review said a certain class of drugs had little clinical benefit, but many Alzheimer’s experts criticized the analysis, saying it unfairly lumped failed drugs with two recently approved treatments.

By Pam Belluck

Effect of ‘gamechanger’ Alzheimer’s drugs ‘trivial’, review concludes

Data assessed from 17 clinical trials of anti-amyloid drugs found no ‘meaningful effect’ on cognitive decline Drugs that have been hailed as a gamechanger for the treatment of Alzheimer’s disease make no noticeable difference to patients, according to an extensive review. The analysis of clinical trials in people with mild cognitive impairment or mild dementia found that the effects of anti-amyloid drugs on cognition and dementia severity over 18 months were “trivial”, with improvements in fu...

By Ian Sample Science editor

Much-hyped Alzheimer’s drugs do not help patients, review finds - The Straits Times

Much-hyped Alzheimer’s drugs do not help patients, review finds  The Straits Times

Alzheimer's drugs make 'no meaningful difference'

Drugs that are said to slow the progression of Alzheimer's disease "make no meaningful difference to patients" while increasing the risk of swelling and bleeding in the brain, according to a new review.

Alzheimer’s drugs targeting amyloid don’t help, review finds

Despite successfully removing amyloid from the brain, the drugs don't improve cognitive function or slow its decline.